The Therapeutic CD38 Monoclonal Antibody Daratumumab Induces Programmed Cell Death via Fcγ Receptor-Mediated Cross-Linking

Marije B Overdijk, J H Marco Jansen, Maaike Nederend, Jeroen J Lammerts van Bueren, Richard W J Groen, Paul W H I Parren, Jeanette H W Leusen, Peter Boross

Research output: Contribution to journalArticleAcademicpeer-review

210 Citations (Scopus)


Emerging evidence suggests that FcγR-mediated cross-linking of tumor-bound mAbs may induce signaling in tumor cells that contributes to their therapeutic activity. In this study, we show that daratumumab (DARA), a therapeutic human CD38 mAb with a broad-spectrum killing activity, is able to induce programmed cell death (PCD) of CD38(+) multiple myeloma tumor cell lines when cross-linked in vitro by secondary Abs or via an FcγR. By comparing DARA efficacy in a syngeneic in vivo tumor model using FcRγ-chain knockout or NOTAM mice carrying a signaling-inactive FcRγ-chain, we found that the inhibitory FcγRIIb as well as activating FcγRs induce DARA cross-linking-mediated PCD. In conclusion, our in vitro and in vivo data show that FcγR-mediated cross-linking of DARA induces PCD of CD38-expressing multiple myeloma tumor cells, which potentially contributes to the depth of response observed in DARA-treated patients and the drug's multifaceted mechanisms of action.

Original languageEnglish
Pages (from-to)807-13
Number of pages7
JournalJournal of Immunology
Issue number3
Publication statusPublished - 1 Aug 2016


  • Journal Article

Cite this